Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863217 | 0.87 | KDM4A (0.43) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 | |
| SCHEMBL2121905 | 0.86 | KDM4A (0.42) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 | |
| SCHEMBL3862106 | 0.86 | CNR2 (0.42) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 | |
| SCHEMBL3861097 | 0.86 | CYP2C19 (0.53) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 | |
| SCHEMBL2121025 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 | |
| SCHEMBL3861821 | 0.85 | HPGD (0.49) | SMN1; SMN2CYP1A2ALDH1A1LMNAHPGD | |
| SCHEMBL3861455 | 0.84 | ADORA2A (0.42) | KDM4AALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4040617 | 0.84 | CACNA1G (0.47) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 | |
| SCHEMBL27612488 | 0.84 | KCNA5 (0.42) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 | |
| SCHEMBL2123513 | 0.84 | NSD2 (0.43) | SMN1; SMN2CYP1A2POLBKDM4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131463-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| CN-1617858-A | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | CN | disclosed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131463-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | SMN1; SMN2 2090/4885CYP1A2 64/4885POLB 4749/4885 |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | SMN1; SMN2 1649/4885CYP1A2 2400/4885POLB 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.